
The Smartest Dividend Stocks to Buy With $500 Right Now
You won't need a lot of money up front to begin raking in dividends from these great stocks.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
You won't need a lot of money up front to begin raking in dividends from these great stocks.
PepsiCo is investing $585 million to raise its Celsius stake to 11%. AbbVie will acquire Gilgamesh Pharmaceuticals' lead investigational candidate for moderate-to-severe major depressive disorder. Bain Capital's Chindata China data center business boasts a valuation of about 30 billion yuan ( ...
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Global Market Current Size Insight In US$ Billion: 2022 - 2030 Global Market Opportunity: > US$ 90 Billion
Unites the Pharma Marketing, PR & Communications, Commercialization and Medical Affairs Communities September 8-11 in Philadelphia
Exton, Pennsylvania, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 ( US ) , research from Spherix Global Insights with U.S. ophthalmologists, including retina specialists, sheds light on urgent, unmet needs across ...
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
AbbVie to pay up to $1.2 billion for Gilgamesh's Phase 2 psychedelic major depressive disorder drug bretisilocin. Phase 2a trial shows strong antidepressant effect and good safety profile. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → AbbVie Inc.
AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline ...
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.
Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer ( ES-SCLC ) marketed by Amgen Royalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager ( BiTE ) , from BeOne Medicines for $885 million upfront.
These great businesses can help patient investors beat the market.
Investors will get great dividends and more with these stocks.
Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This week, Benzinga's proprietary Growth data highlighted major swings among household names. See what to trade after Powell's next speech and how to time the market's reaction.
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term growth.
Sit back and let the income roll in with this great exchange-traded fund.
These exchange-traded funds can provide a solid foundation for your portfolio.
Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite headwinds.
An official report on August 20, 2025 reveals Representative Ritchie Torres's recent purchase of AbbVie ABBV stock, valued between $78,078 and $1,170,000. The transaction took place on September 26, 2024, as per the August filing. At this time, AbbVie shares are trading up 1.0% at $211.25.
Rinvoq helped up to 55% of alopecia patients regain 80%+ scalp hair by week 24. Safety profile remained consistent, with low discontinuation rates in both dose groups. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and ...
These high-yield dividend stocks are built to last.
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, ...
Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
You'd be sitting pretty right now.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks.
Marjorie Taylor Greene recently bought UnitedHealth shares. The purchase came before investors Warren Buffett and Michael Burry revealed new stakes in the company. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
AbbVie ABBV has outperformed the market over the past 5 years by 2.74% on an annualized basis producing an average annual return of 16.46%. Currently, AbbVie has a market capitalization of $362.01 billion.
Xilio Therapeutics ( NASDAQ:XLO ) , a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies, reported its Q2 2025 results on August 14, 2025. The company reported collaboration and license revenue ( GAAP ) of $8.1 million, up sharply from $2.4 million ( GAAP ) ...
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 ...
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
Image source: The Motley Fool.Thursday, July 31, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.
These tried-and-true businesses are performing well against a volatile backdrop.
Investing in quality dividend ETFs can offer a great way to boost your portfolio returns.
The funds listed here offer a good mix of safety, diversification, and dividends.